

AHCL/ SE/6/2026-27

May 8, 2026

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031
Symbol: AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting


In terms of Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **May 8, 2026** had, inter-alia:

- (i) Approved the Audited Financial Results for the quarter and year ended March 31, 2026, as recommended by the Audit Committee at its meeting held today 8 May 2026. The same along with the Independent Auditor's Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
 - (ii) Recommended Final Dividend of Rs. 2.90 per equity share on 2,89,10,630 shares of Re. 1/- each fully paid up for the financial year 2025-26. The Final dividend, if approved at the Annual General Meeting, will be paid to the eligible shareholders within 30 days of AGM.
 - (iii) Approved the appointment of Mr. Ramaswami Krishnan (DIN: 08562199) as an Additional Director designated as Non-Executive Independent Director of the Company with effect from 8 May 2026, based on the recommendation of the Nomination and Remuneration Committee. Mr. Ramaswami Krishnan is appointed as Non-Executive Independent Director for period of five (5) consecutive years with effect from 8 May 2026 to 7 May 2031, subject to approval of the shareholders.
 - (iv) Approved the re-appointment of Mr. Muralidharan Swayambunathan (DIN: 09198315) as Non-Executive Independent Director of the Company, based on the recommendation of the Nomination and Remuneration Committee for the second and final term of five (5) consecutive years from 29 June 2026 to 28 June 2031, subject to the approval of the shareholders.
- The Board of Directors have also approved the draft postal ballot notice for the appointment of Mr. Ramaswami Krishnan and the re-appointment of Mr. Muralidharan Swayambunathan.
- (v) Approved the rolling out of the revised Second Phase "ESOP 2" of the existing ESOP Scheme of the company by the name of "Amrutanjan Health Care Limited – Employees Stock Option Scheme 2020" (Scheme").

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel :+91-44 - 2499 4465
+91-44 • 2466 9000
Fax :+91-44 - 2499 4585

E-mail :customercare@amrutanjan.com
WebSite : www. amrutanjan.com
Toll Free No.: 1 • 800 - 425 - 4545
CIN-L24231TN1936PLC000017



(vi) Approved the appointment M/s. PKF Sridhar & Santhanam, Chartered Accountants as Internal Auditors as recommended by the Audit Committee for the financial year 2026-2027 pursuant to the provisions of Section 138 of the Companies Act, 2013 read with Rule 13 of Companies (Accounts) Rules, 2014.

The Board Meeting commenced at 12:45 p.m. and concluded at 4:30 p.m. Request you to kindly take the same on record.

Thanking you,


Yours faithfully,
For **Amrutanjan Health Care Limited**

Gagan Preet Singh
General Manager - Legal
Company Secretary and Compliance Officer

Amrutanjan Health Care Limited

103, (Old No.42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel :+91-44 - 2499 4465
+91-44 • 2466 9000
Fax :+91-44 - 2499 4585

E-mail :customercare@amrutanjan.com
WebSite : www.amrutanjan.com
Toll Free No.: 1 • 800 - 425 - 4545
CIN-L24231TN1936PLC000017



**INTEGRATED FILING (FINANCIAL) FOR THE QUARTER AND YEAR
ENDED 31ST MARCH, 2026**

Sl. No.	Particulars	Remarks
1	Financial Results: Audited Financial Results for the quarter and year ended 31st March, 2026 (Standalone)	Enclosed
2	Statement on Deviation or Variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.,	Not Applicable
3	Format for disclosing outstanding default on loans and debt securities	Not Applicable
4	Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)	Enclosed in XBRL
5	Statement on impact of audit qualifications (for audit report with modified opinion) submitted along - with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	Not Applicable
6	Declaration that the Auditor's Report of Annual Financial Results of the Company is with unmodified opinion	Enclosed

Amrutanjan Health Care Limited

103, (Old No.42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel :+91-44 - 2499 4465
+91-44 • 2466 9000
Fax :+91-44 - 2499 4585

E-mail :customercare@amrutanjan.com
WebSite : www.amrutanjan.com
Toll Free No.: 1 • 800 - 425 - 4545
CIN-L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Audited Financial Results for the quarter and year ended 31 March 2026

(Amount in INR in Lakhs)

Particulars	Quarter ended			Year ended	
	31 March 2026 (Audited - refer note 7)	31 December 2025 (Unaudited)	31 March 2025 (Audited - refer note 7)	31 March 2026 (Audited)	31 March 2025 (Audited)
I Revenue from operations	14,976.81	14,103.87	13,541.36	50,255.27	45,181.63
II Other income	473.06	411.96	481.93	1,757.39	1,767.87
III Total income (I + II)	15,449.87	14,515.83	14,023.29	52,012.66	46,949.50
IV Expenses					
(a) Cost of materials consumed	3,130.01	2,876.68	3,494.97	10,642.70	10,059.69
(b) Purchase of stock-in-trade	4,098.44	3,329.31	3,093.08	14,063.09	12,317.94
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	123.83	173.36	311.33	(269.64)	(56.90)
(d) Employee benefits expense	1,564.93	1,614.93	1,601.73	6,376.25	5,910.27
(e) Finance cost	4.59	4.79	4.33	19.50	21.92
(f) Depreciation and amortisation expense	160.62	162.44	162.22	631.90	652.61
(g) Other expenses					
- Advertisement and selling expenditure	1,757.98	2,133.96	1,587.73	6,003.83	5,611.04
- Others	1,747.35	1,458.79	1,682.33	5,870.58	5,519.53
Total expenses (IV)	12,587.75	11,754.26	11,937.72	43,338.21	40,036.10
V Profit before exceptional item & tax (III - IV)	2,862.12	2,761.57	2,085.57	8,674.45	6,913.40
VI Exceptional Item					
Lease rent (refer Note 10)	760.50	-	-	760.50	-
Impact of New labour codes (refer Note 11)	-	125.17	-	125.17	-
VII Profit before tax (V - VI)	2,101.62	2,636.40	2,085.57	7,788.78	6,913.40
VIII Tax expenses	482.34	691.18	567.79	1,997.00	1,829.93
IX Profit after tax (V - VI)	1,619.28	1,945.22	1,517.78	5,791.78	5,083.47
X Other comprehensive income / (loss)					
Items that will not be reclassified subsequently to profit or loss					
Re-measurement gain/(loss) on defined benefit plans	14.95	0.15	(5.46)	(18.50)	(105.87)
Income tax relating to items that will not be reclassified to profit or loss	(3.76)	(0.04)	1.38	4.66	26.65
Other comprehensive income/ (loss), net of taxes	11.19	0.11	(4.08)	(13.84)	(79.22)
XI Total comprehensive income for the period / year (VII + VIII)	1,630.47	1,945.33	1,513.70	5,777.94	5,004.25
Equity share capital (Face value INR 1/- each, fully paid up)	289.11	289.11	289.11	289.11	289.11
Other equity				36,734.15	32,372.35
Earnings per equity share					
Basic earnings per share (INR)	5.60	6.73	5.25	20.03	17.58
Diluted earnings per share (INR)	5.60	6.73	5.25	20.03	17.58
	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
<i>See accompanying notes to Audited financial results</i>					



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Note 1: Statement of assets and liabilities

(Amount in INR in Lakhs)

S. No.	Particulars	As at	As at
		31 March 2026	31 March 2025
		Audited	Audited
A	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	4,829.93	4,584.52
	(b) Right-of-use assets	150.81	188.28
	(c) Capital work in progress	10,547.98	1,619.78
	(d) Intangible assets	144.75	167.81
	(e) Intangible assets under development	23.70	5.00
	(f) Financial assets		
	Investments	4.67	4.51
	Other financial assets	4,619.09	4,165.29
	(g) Deferred tax assets (net)	531.46	311.17
	(h) Other tax assets (net)	290.56	260.05
	(i) Other non-current assets	581.53	1,765.37
	Total non-current assets	21,724.48	13,071.78
2	Current assets		
	(a) Inventories	3,735.04	2,725.98
	(b) Financial assets		
	(i) Investments	307.40	-
	(ii) Trade receivables	6,064.40	5,582.18
	(iii) Cash and cash equivalents	1,127.23	1,015.52
	(iv) Bank balances other than (iii) above	2,205.23	7,300.10
	(v) Other financial assets	14,234.00	11,617.07
	(c) Other current assets	1,491.32	826.15
	Total current assets	29,164.62	29,067.00
	Total assets (1+2)	50,889.10	42,138.78
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	289.11	289.11
	(b) Other equity	36,734.15	32,372.35
	Total equity	37,023.26	32,661.46
2	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	Lease liabilities	142.32	167.63
	Other financial liabilities	103.06	21.50
	(b) Provisions *	1,002.01	829.89
	Total non-current liabilities	1,247.39	1,019.02
3	Current liabilities		
	(a) Financial liabilities		
	Lease liabilities	35.42	40.18
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	337.50	193.97
	total outstanding dues of creditors other than micro enterprises and small enterprises	6,752.00	6,710.30
	Other financial liabilities	2,936.74	168.44
	(b) Other current liabilities	992.85	944.57
	(c) Provisions	1,056.68	233.65
	(d) Current tax liabilities (net)	507.26	167.19
	Total current liabilities	12,618.45	8,458.30
	Total liabilities (2+3)	13,865.84	9,477.32
	Total equity and liabilities (1+2+3)	50,889.10	42,138.78



Note 2: Statement of Cash flows for the year ended 31 March 2026

Particulars	(Amount in INR in Lakhs)	
	For the year ended 31 March 2026	For the year ended 31 March 2025
	Audited	Audited
Cash flow from operating activities		
Profit before tax	7,788.78	6,913.40
Adjustments for:		
Depreciation and amortisation expense	631.90	652.61
Profit on sale of property, plant and equipment	(10.38)	-
Equity-settled share-based payment transactions	(93.42)	114.50
Loss allowance on trade receivables	91.52	25.97
Bad debts written off	0.15	0.42
Change in fair value of financial assets at FVTPL	(7.56)	(0.20)
Interest income on cash and cash equivalents and other bank balances	(1,473.71)	(1,446.57)
Interest income on corporate debt securities and loans at amortised cost	(118.33)	(158.15)
Interest income on debt instruments	-	(0.02)
Excess provision written back, net	(107.20)	(143.69)
Finance costs	19.50	21.92
Operating profit before working capital / other changes	6,721.25	5,980.19
Working capital adjustments:		
(Increase) in trade receivables	(573.89)	(819.63)
(Increase) in other assets	(904.87)	(83.78)
(Increase) in other financial assets	(50.95)	(2.35)
(Increase) / decrease in inventories	(1,009.06)	164.49
Increase in other financial liabilities	-	12.65
Increase in provisions	976.65	64.69
Increase in trade payables	292.43	1,461.70
Increase in other liabilities	48.28	104.21
Cash generated from operating activities	(1,221.41)	901.98
Less: Income tax paid (net)	5,499.84	6,882.17
Net cash generated from operating activities (a)	(1,903.07)	(1,792.25)
	3,596.77	5,089.92
Cash flows from investing activities		
Purchase or construction of property, plant and equipment, intangible assets, capital work-in progress, intangible assets under development, movement in capital advances and payable towards purchase of property, plant and equipment (including retention payable)	(5,500.38)	(3,555.29)
Proceeds from sale of Property, plant and equipment	10.38	-
Redemption / (Investment) in bank deposits and financial institutions	2,075.09	(1,146.16)
Interest received on deposits with banks and financial institutions, net	1,592.04	1,604.74
(Investments made) / Proceeds from redemption of investments	(300.00)	0.05
Interest received on debt instruments	-	0.02
Net cash (used in) investing activities (b)	(2,122.87)	(3,096.64)
Cash flow from financing activities		
Dividend paid	(1,319.80)	(1,326.65)
Sale of shares by employee stock option trust	7.18	23.78
Payment of lease liabilities	(49.57)	(46.09)
Net cash (used in) financing activities (c)	(1,362.19)	(1,348.96)
Net change in cash and cash equivalents (a) + (b) + (c)	111.71	644.32
Cash and cash equivalents at the beginning of the year	1,015.52	371.20
Effect of exchange rate fluctuations on cash held	-	-
Cash and cash equivalents at the end of the year	1,127.23	1,015.52
Components of cash and cash equivalents		
Cash on hand	3.06	3.70
Bank balances	1,124.17	1,011.82
Cash and cash equivalents as per Statement of assets and liabilities	1,127.23	1,015.52

Note: The above cash flow statement has been prepared under the "indirect method" as set out in the Ind AS 7 on statement of Cash Flows specified under section 133 of the Companies Act, 2013



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

3. The above audited financial results for the quarter and year ended 31 March 2026 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 8 May 2026. The statutory auditors have audited the above results and issued an unmodified opinion.
4. These audited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results
6. During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above, at its meeting held on 23 May 2024. The Compensation Committee has withdrawn the "ESOP 2 Scheme" due to non - satisfaction of vesting conditions (Turnover) and unfavorable movement in the market price of the shares. In line with Ind AS 102, the impact of such cancellation amounting to INR 269.16 Lakhs is recognised in the Statement of Profit and Loss such that the cumulative expense reflects the cost of vested options, with a corresponding adjustment to share based payment reserve.
7. The figures for the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial years and published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review.
8. Interim dividend of INR.1/- per share, aggregating to INR.289.11 lakhs has been paid during the quarter ended 31 March 2026. The Board of Directors at its meeting held on 8 May 2026, has proposed a final dividend of INR 2.90 per share.
9. The audited financial results of the Company for the Quarter/Year ended 31 March 2026 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com
10. During the financial year 2005-06, the Government of Tamil Nadu retrospectively revised the lease rent for a leasehold land, effective from November 2001, by determining fair rent under Section 34A of the Tamil Nadu Hindu Religious and Charitable Endowments Act, 1959. Pursuant to this revision, a demand notice was issued to the Company. Accordingly, the Company had filed a Writ Petition before the High Court of Judicature, Madras challenging the fair rent determination, contending that the revision was exorbitant and not legally tenable. On 25 September 2025, the High Court of Judicature, Madras dismissed the petition and upheld the rent fixed by the Fair Rent Committee constituted by the Government of Tamil Nadu. Based on the advice from the external consultant, the Company filed an appeal on 9 December 2025 before the Division Bench of the High Court of Judicature, Madras and the appeal was dismissed on 16 March 2026. Accordingly the Company has created a provision and presented under "Exceptional Item". This is an one time impact as the possession of land was already handed over to the Government of Tamil Nadu in May 2018.
11. On 21 November 21 2025, the Government of India has notified four Labour codes - the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020 and the Occupational safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed for the incremental impact of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Impact of new Labour Codes" under "Exceptional items" in the financial results for the year ended 31 March 2026. The incremental impact consisting of gratuity and leave encashment benefits of INR 125.17 lakhs, primarily arising due to change in wage definition. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

12. Segment reporting in the audited financial results: Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segment (represents Pain Management Centre), pursuant to launch of New products Women's Hygiene is renamed as Women's Hygiene & Personal Care.

Particulars	(Amount in INR in Lakhs)				
	Quarter ended			Year ended	
	31 March 2026 (Audited - refer note 7)	31 December 2025 (Unaudited)	31 March 2025 (Audited - refer note 7)	31 March 2026 (Audited)	31 March 2025 (Audited)
1 Segment revenue					
a OTC Products					
b Women's Hygiene & Personal Care	9,078.63	10,054.02	8,278.34	32,831.73	29,002.99
c Beverages	4,183.90	3,667.97	3,445.55	13,990.66	12,396.25
d Others	1,641.84	309.40	1,766.97	3,156.09	3,643.01
Total	72.44	72.48	50.50	276.79	139.38
2 Segment results	14,976.81	14,103.87	13,541.36	50,255.27	45,181.63
a OTC Products					
b Women's Hygiene & Personal Care	2,671.64	2,752.54	2,026.01	8,344.36	6,557.17
c Beverages	(128.90)	(32.37)	(177.23)	(272.16)	(391.05)
d Others	81.88	(352.05)	34.40	(634.86)	(243.56)
Total	(3.56)	(4.47)	(22.72)	(27.64)	(81.43)
Less: Finance cost	2,621.06	2,363.65	1,860.46	7,409.70	5,841.13
Add: Interest income net of other unallocable expenditure	4.59	4.79	4.33	19.50	21.92
Total profit before tax	(514.85)	277.54	229.44	398.58	1,094.19
3 Segment assets	2,101.62	2,636.40	2,085.57	7,788.78	6,913.40
a OTC Products					
b Women's Hygiene & Personal Care	7,897.10	7,254.27	6,800.73	7,897.10	6,800.73
c Beverages	13,593.47	7,939.62	5,209.00	13,593.47	5,209.00
d Others	3,376.12	2,387.88	3,503.26	3,376.12	3,503.26
e Unallocated assets	120.38	129.50	122.13	120.38	122.13
Total	25,902.03	27,412.37	26,503.68	25,902.03	26,503.68
4 Segment liabilities	50,889.10	45,123.64	42,138.80	50,889.10	42,138.80
a OTC Products					
b Women's Hygiene & Personal Care	5,726.00	6,034.67	5,539.80	5,726.00	5,539.80
c Beverages	4,739.52	1,418.48	1,646.36	4,739.52	1,646.36
d Others	1,576.29	794.98	1,359.50	1,576.29	1,359.50
e Unallocated liabilities	36.90	42.98	42.67	36.90	42.67
Total	1,787.13	925.26	889.01	1,787.13	889.01
Total capital employed in the Company	13,865.84	9,216.37	9,477.34	13,865.84	9,477.34
	37,023.26	35,907.27	32,661.46	37,023.26	32,661.46

For Amrutanjan Health Care Limited


S Sambhu Prasad
Chairman & Managing Director
DIN: 00015729

Date: 08 May 2026
Place: Chennai

Independent Auditor's Report

To the Board of Directors of Amrutanjan Health Care Limited

Report on the audit of the Annual Financial Results

Opinion

We have audited the accompanying annual financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, (in which are included the financial statements of Amrutanjan Health Care Limited ESOP Trust ("ESOP trust")) being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the annual financial results.

Management's and Board of Directors'/ Board of Trustees' Responsibilities for the Annual Financial Results

These annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and the Board of Directors of the Company/Board of Trustees of the ESOP trust are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company/ESOP trust and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively

Independent Auditor's Report (Continued)
Amrutanjan Health Care Limited

for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the respective Management and the Board of Directors/Board of Trustees are responsible for assessing the Company's/ESOP trust's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/Board of Trustees either intends to liquidate the Company/ESOP trust or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors/Board of Trustees are responsible for overseeing the financial reporting process of the Company/ESOP trust.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Independent Auditor's Report (Continued)
Amrutanjan Health Care Limited

Other Matter(s)

- a. The annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



R Kalyana Sundara Rajan

Partner

Membership No.: 221822

UDIN:26221822EGXKYJ5654

Chennai

08 May 2026



ANNEXURE

DECLARATION

**Pursuant to Regulation 33 (d) of the SEBI (Listing Obligations and Disclosure Requirements),
Regulations, 2015**

It is hereby declared and confirmed that the Auditor's Report of Annual Financial Results of the Company is with unmodified opinion.

This declaration is furnished in reference to the provision to clause (d) of Sub-Regulation (3) of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


This is for your records.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited

**N Swaminathan
Chief Financial Officer
Date : 08.05.2026**



ANNEXURE I

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/CIR/2023/123 dated July 13, 2023

Appointment of Additional Director


Name	Mr. Ramaswami Krishnan
Reason for Change (appointment, re- appointment, resignation, removal, death or otherwise)	Appointment of Mr. Ramaswami Krishnan (DIN: 08562199) as an Additional Director designated as Non-Executive Independent Director.
Date of Appointment	With effect from 8 May 2026 for a period of five years subject to shareholders approval.
Brief Profile (in case of appointment)	Mr. Ramaswami Krishnan is 65 years of age and is a qualified CA, CS and CWA by profession. In addition, he also holds a Ph. D. degree and a Master Degree in Business Administration. He was earlier associated with RSL Industries Limited, Nagarjuna Group. In his last assignment, he was associated with Malladi Drugs and Pharmaceuticals Limited as Director Finance & Marketing and Company Secretary.
Disclosure of Relationship between Directors (in case of appointment of a director).	Not Related to any other directors of Amrutanjan Health Care Limited

As per the provisions of the Companies Act, 2013 and the Listing Regulations, Mr. Ramaswami Krishnan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel :+91-44 - 2499 4465
+91-44 • 2466 9000
Fax :+91-44 - 2499 4585

E-mail :customercare@amrutanjan.com
WebSite : www.amrutanjan.com
Toll Free No.: 1 • 800 - 425 - 4545
CIN-L24231TN1936PLC000017



ANNEXURE II

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/CIR/2023/123 dated July 13, 2023

Re-appointment of Non-Executive Independent Director

Name	Mr. Muralidharan Swayambunathan
Reason for Change (appointment, re- appointment, resignation, removal, death or otherwise)	Re-appointment of Mr. Muralidharan Swayambunathan (DIN: 09198315) as Non-Executive Independent Director for a second and final term of five consecutive years.
Date of Appointment	Re-appointment to second and final term with effect from 29 June 2026 for a period of five years subject to shareholders approval.
Brief Profile (in case of appointment)	Mr. Muralidharan Swayambunathan is a qualified Company Secretary from India and UK and he has 37+ years of experience in various industries in India and abroad. His career span has been across reputed organizations including TVS Sundaram Clayton Group Companies, Amrutanjan and also International retail duty free group abroad and has expertise in Corporate Secretarial, Corporate Governance, Risk Management, Finance, Legal and General Management.
Disclosure of Relationship between Directors (in case of appointment of a director).	Not Related to any other directors of Amrutanjan Health Care Limited

As per the provisions of the Companies Act, 2013 and the Listing Regulations, Mr. Muralidharan Swayambunathan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

Amrutanjan Health Care Limited

103, (Old No.42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel :+91-44 - 2499 4465
+91-44 • 2466 9000
Fax :+91-44 - 2499 4585

E-mail :customercare@amrutanjan.com
WebSite : www.amrutanjan.com
Toll Free No.: 1 • 800 - 425 - 4545
CIN-L24231TN1936PLC000017